Dimensional Fund Advisors LP Buys 238,075 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Dimensional Fund Advisors LP increased its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 15.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,802,364 shares of the company's stock after buying an additional 238,075 shares during the period. Dimensional Fund Advisors LP owned 1.23% of MiMedx Group worth $17,338,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Jump Financial LLC bought a new stake in MiMedx Group in the 4th quarter valued at about $154,000. XTX Topco Ltd acquired a new position in MiMedx Group in the 4th quarter valued at approximately $386,000. Raymond James Financial Inc. acquired a new position in MiMedx Group in the 4th quarter valued at approximately $887,000. Renaissance Technologies LLC boosted its stake in shares of MiMedx Group by 18.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock valued at $17,360,000 after purchasing an additional 280,327 shares during the last quarter. Finally, Cannell Capital LLC boosted its stake in shares of MiMedx Group by 1.1% in the 4th quarter. Cannell Capital LLC now owns 3,639,545 shares of the company's stock valued at $35,012,000 after purchasing an additional 40,235 shares during the last quarter. Institutional investors own 79.15% of the company's stock.

Insider Activity at MiMedx Group

In other news, CEO Joseph H. Capper bought 200,000 shares of the firm's stock in a transaction that occurred on Friday, May 2nd. The shares were acquired at an average price of $6.34 per share, with a total value of $1,268,000.00. Following the acquisition, the chief executive officer now owns 529,530 shares of the company's stock, valued at approximately $3,357,220.20. The trade was a 60.69% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the transaction, the insider now directly owns 310,836 shares in the company, valued at $2,452,496.04. The trade was a 1.30% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 144,018 shares of company stock worth $1,130,312. 1.30% of the stock is owned by corporate insiders.

MiMedx Group Stock Down 0.6%

Shares of MDXG traded down $0.04 during trading hours on Tuesday, reaching $7.21. 213,598 shares of the stock traded hands, compared to its average volume of 694,412. The company has a market cap of $1.06 billion, a price-to-earnings ratio of 13.11 and a beta of 1.85. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a 52 week low of $5.47 and a 52 week high of $10.14. The stock has a fifty day simple moving average of $7.26 and a 200 day simple moving average of $8.16.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting the consensus estimate of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. On average, equities analysts forecast that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on MDXG shares. Cantor Fitzgerald reissued an "overweight" rating and set a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th. StockNews.com cut shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a report on Friday.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.